ViroGates Introduces a Life-saver to the European Market

ViroGates launches the suPARnostic® ELISA test kit for commercial use in infectious diseases in Europe.

ViroGates has, over the past week, signed two exclusive distribution deals with carefully selected partners to market its suPARnostic® kit in Europe. Ramcon A/S will cover the home markets of Denmark and Sweden and INyDIA Biomedical will cover two further European markets - Spain and Portugal.

- suPARnostic® is a novel solution to serve the world; a tool that addresses an open demand in many lifethreatening infectious diseases, says Betina Macho, CEO, ViroGates.

Furthermore she stresses that due to an extremely high interest from all sides, Virogates will continue to execute further distribution agreements over the coming months. At present Virogates is in discussion with other potential European partners and is also preparing a product launch in Asia and Africa, where suPARnostic® provides an affordable and practical solution for resource-poor settings

suPARnostic was invented and developed in Denmark and South Africa and was originally intended to be a tool for monitoring HIV progression and treatment response, but has during its development revealed amazing potential as a prognostic tool in other infectious diseases including tuberculosis and sepsis.

For further information visit the Virogates website. 

Source: Press release, Virogates, 07.01.2008